State Street Corp Lineage Cell Therapeutics, Inc. Transaction History
State Street Corp
- $2.21 Trillion
- Q1 2024
A detailed history of State Street Corp transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 2,177,209 shares of LCTX stock, worth $2.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,177,209
Previous 2,096,609
3.84%
Holding current value
$2.31 Million
Previous $2.29 Million
41.01%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding LCTX
# of Institutions
124Shares Held
93.5MCall Options Held
21.4KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$44.2 Million4.66% of portfolio
-
Black Rock Inc. New York, NY8.49MShares$9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.37MShares$8.88 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA6.25MShares$6.63 Million0.86% of portfolio
-
Defender Capital, Llc.4.97MShares$5.27 Million2.61% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $180M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...